Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HB0025 |
Synonyms | |
Therapy Description |
HB0025 is a bispecific antibody comprised of a monoclonal antibody targeting CD274 (PD-L1) fused to extracellular domain 2 of VEGFR1 to target VEGF, which potentially inhibits tumor growth (PMID: 34925354). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HB0025 | HB-0025|HB 0025 | PD-L1/PD-1 antibody 121 VEGF Antibody 12 | HB0025 is a bispecific antibody comprised of a monoclonal antibody targeting CD274 (PD-L1) fused to extracellular domain 2 of VEGFR1 to target VEGF, which potentially inhibits tumor growth (PMID: 34925354). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04678908 | Phase I | HB0025 | A Study of Injection HB0025 in Patients With Advanced Solid Tumors | Unknown status | USA | 1 |